Updated on 19 September 2016
Munich: Danish Drug maker Novo Nordisk recently announced that patients treated with Semaglutide, an investigational glucagon-like peptide 1 analogue administered once-weekly, reduces the risk of cardiovascular problems by 26% among type 2 Diabetic patients with high CV risk.
Semagutide significantly reduced the risk of the primary composite endpoint of time to first occurrence of either cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke by 26% vs placebo, when added to standard of care in 3,297 adults with type 2 diabetes at high CV risk, the drug maker company said.
This was announced by Steven P Marso, Medical Director, Cardio Vascular Services, HCA Midwest Health, US, and the principal investigator of 3200-patient SUSTAIN trials conducted in 22 countries, while presenting the main results of the trial at the 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2016 held recently at Munich, Germany. The results have also been published in the New England Journal of Medicine.
The lower cardiovascular risk was principally driven by a significant 39% decrease in nonfatal stroke and a 26% reduction in nonfatal MI (nonsignificant); there was no difference in cardiovascular deaths between the different arms of the trial - 0.5 mg of semaglutide once weekly, 1.0 mg of semaglutide once weekly, and corresponding placebo groups.
"The reduction in cardiovascular events observed with semaglutide in SUSTAIN 6 is notable given the small study population and the short trial duration," said Dr Marso. "These findings are clinically relevant, as cardiovascular disease is the leading cause of death in people with type 2 diabetes and new treatment options that can also reduce the risk of cardiovascular events are needed."